Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.64 |
| ▸ | DPP4 | P27487 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45498 | 1.00 | S1PR2 (0.64) | S1PR2S1PR1DPP4ANPEPERAP1 | |
| SCHEMBL288680 | 1.00 | S1PR2 (0.64) | S1PR2S1PR1DPP4ANPEPERAP1 | |
| Hydrochloric Acid SCHEMBL1927328 | 0.98 | S1PR2 (0.62) | S1PR2S1PR1DPP4ANPEPERAP1 | |
| SCHEMBL27453353 | 0.89 | S1PR2 (0.60) | S1PR2S1PR1ANPEPERAP1ERAP2 | |
| SCHEMBL1669596 | 0.89 | S1PR2 (0.60) | S1PR2S1PR1ANPEPERAP1ERAP2 | |
| SCHEMBL6049800 | 0.87 | S1PR2 (0.63) | S1PR2S1PR1DPP4MMP12MMP2 | |
| SCHEMBL1105478 | 0.85 | ALDH1A1 (0.53) | S1PR2S1PR1DPP4ANPEPERAP1 | |
| SCHEMBL27999568 | 0.85 | S1PR2 (0.65) | S1PR2S1PR1DPP4ANPEPERAP1 | |
| SCHEMBL289093 | 0.85 | S1PR2 (0.65) | S1PR2S1PR1DPP4ANPEPERAP1 | |
| SCHEMBL6467442 | 0.84 | S1PR2 (0.63) | S1PR2S1PR1DPP4MMP12MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| EP-1646718-A2 | METHODS FOR THE STEREOSELECTIVE SYNTHESIS AND ENANTIOMERIC ENRICHMENT OF B-AMINO ACIDS | Pharmacia Corporation (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005633-A2 | METHODS FOR THE STEREOSELECTIVE SYNTHESIS AND ENANTIOMERIC ENRICHMENT OF B-AMINO ACIDS | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009151-A1 | Methods for the stereospecific and enantiomeric enrichment of beta-amino acids | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1082302-B1 | A VLA-4 INHIBITOR: OMEPUPA-V | BIOGEN INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6495525-B1 | N-((4-(((2-METHYLPHENYLAMINO)CARBONYL)AMINO)PHENYL)ACETYL)-L -PROLYL-3-METHYL)-BETA-ALANINE; VERY LATE ANTIGEN-4 CELL ADHESION INHIBITOR; INFLAMMATION AND IMMUNE REACTIONS | BIOGEN, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1082302-A1 | A VLA-4 INHIBITOR: OMEPUPA-V | BIOGEN, INC. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061421-A1 | A NOVEL VLA-4 INHIBITOR: oMePUPA-V | BIOGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5952306-A | INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | S1PR2 2052/4885S1PR1 1863/4885DPP4 1357/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | S1PR2 3371/4885S1PR1 3841/4885DPP4 1217/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | S1PR2 2844/4885S1PR1 2366/4885DPP4 1271/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | S1PR2 2613/4885S1PR1 3182/4885DPP4 1374/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | S1PR2 4799/4885S1PR1 4776/4885DPP4 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.